KCSVEN, Hickma is projecting on assumptions that they will capture the Vascepa market which includes ReduceIt CVD label scripts to reach that value. There’s no way that they think the high triglyceride >500 would have those value estimations. They are implying that they expect a very large part of that estimate. That’s proof that they expect to infringe and shows motive and intent to infringe on the ReduceIt population scripts. They clearly show and allude to the fact that they are attempting to make generic Vascepa and state clearly that 500 plus million is the potential annual market they will be going after. That’s the way I see it anyway.
Market Data 
Markets 
AI
